Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long term response with immune-checkpoint blockade.

Keyphrases

nk cells
dendritic cells
induced apoptosis
regulatory t cells
human health
oxidative stress
cell proliferation
climate change
signaling pathway
risk assessment